VSTMVerastem, Inc.
Pharmaceutical Preparations
- Revenue
- $31M
- 209% YoY
- Operating margin
- -550.3%
- 52% YoY
- EBITDA
- −$170M
- 48% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$106M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired30% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $2M | $3M | — | $10M | $31M | 209% |
| Operating income | −$61M | −$73M | −$92M | −$115M | −$170M | 48% |
| Net income | −$71M | −$74M | −$87M | −$131M | −$209M | 60% |
| Operating cash flow | −$54M | −$64M | −$86M | −$105M | −$138M | 31% |
| Capex | $196K | — | — | $28K | — | |
| Stock-based comp | $8M | $6M | $6M | $7M | $9M | 28% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $374K · 3
- Net
- −$374K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 160 | — |
| FY2024 | — | — | 107 | — |
| FY2023 | — | — | 169 | — |